PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

Triple-negative breast cancer (TNBC) is characterised by poor outcomes and a historical
lack of targeted therapies. Dysregulation of signalling through the phosphoinositide 3 (PI3) …

Since its discovery as the elusive tumor suppressor gene at the frequently mutated 10q23
locus, PTEN has been identified as lost or mutated in several sporadic and heritable tumor …

Pten/Mmac1+/− heterozygous mice exhibited neoplasms in multiple organs including the
endometrium, liver, prostate, gastrointestinal tract, thyroid, and thymus. Loss of the wild-type …

Abstract PTEN, on 10q23. 3, encodes a major lipid phosphatase which signals down the
phosphoinositol‐3‐kinase/Akt pathway and effects G1 cell cycle arrest and apoptosis …

PTEN, a tumor suppressor located at chromosome 10q23, is mutated in a variety of sporadic
cancers and in two autosomal dominant hamartoma syndromes. PTEN is a phosphatase …

Abstract PTEN/MMAC1 (phosphatase, tensin homologue/mutated in multiple advanced
cancers) is a tumor suppressor protein that has sequence homology with dual-specificity …

The PTEN tumor suppressor was discovered by its homozygous deletion and other
mutations in cancer. Since then, PTEN has been shown to be a non-redundant …

Introduction: The PTEN gene, a candidate tumor suppressor, is localized to chromosome
10q23 and shares extensive homology with cytoskeletal proteins auxilin and tensin. A high …

Germline mutations in PTEN, encoding a dual-specificity phosphatase on 10q23. 3, cause
Cowden syndrome (CS), which is characterized by a high risk of breast and thyroid cancers …